« Previous Next »Gastroenterology
Volume 136, Issue 7 , Pages 2169-2179.e4, June 2009

Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

Patrick Marcellin
- Service d'Hépatologie, U773-CRB3, Hôpital Beaujon, University of Paris, Clichy, France
- Reprint requests Address requests for reprints to: Prof Patrick Marcellin, Service d'Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, Clichy, France. 100 boulevard du Général Leclerc, 92110 Clichy, France. fax: xxx
Ferruccio Bonino
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico di Milano, Italy
George K.K. Lau
- Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
Patrizia Farci
- Universita di Cagliari, Cagliari, Italy
Cihan Yurdaydin
- University of Ankara, Faculty of Medicine, Ankara, Turkey
Teerha Piratvisuth
- NKC Institute of Gastroenterology and Hepatology, Department of Internal Medicine, Songklanagarind Hospital, Prince of Songkla University, Hat Yai 90110, Thailand
Rui Jin
- Digestive Department, Beijing You-An Hospital, Beijing, China
Selim Gurel
- Department of Gastroenterology, Uludag University, Bursa, Turkey
Zhi-Meng Lu
- Department of Infectious Diseases, Ruijin Hospital, Shanghai, China
Jian Wu
- Roche, Dee Why, Australia
Matei Popescu
- F. Hoffman-La Roche, Basel, Switzerland
Stephanos Hadziyannis
- Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group

Received 13 June 2008; accepted 2 March 2009. published online 20 March 2009.

Full Text Available

This article has an accompanying continuing medical education activity on page 2388. Learning Objective: Upon completion of this exercise, successful learners will be able to assess the likelihood of sustained response, 3 years post-treatment in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a, and will be able to utilize this knowledge when assessing the potential treatment options and deciding upon the most appropriate course of management for their patients with chronic hepatitis B.

Conflicts of interest The authors disclose the following: Dr Marcellin has received consulting and lecture fees from Roche, and grants from Roche, Dr Bonino has received consulting fees from Roche; Dr Lau received consulting fees from Roche, and GlaxoSmithKline, and lecture fees from Roche, and GlaxoSmithKline, Dr Farci has received consulting fees from Roche; Dr Yurdaydin, Dr Piratvisuth, Dr Jin, Dr Gurel, Dr Hadziyannis, and Dr Lu have received grant support from Roche. Mr Wu and Dr Popescu report being employees of Roche.

Funding Supported by a research grant from F. Hoffmann-La Roche, Basel, Switzerland.

PII: S0016-5085(09)00377-1

doi:10.1053/j.gastro.2009.03.006